Carlsbad, CA, April 06, 2023 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that the Canadian Intellectual Property Office (CIPO) has issued Canadian Patent No. 2,942,358 titled, “Compositions for the Treatment of Autodigestion.” This key patent covers the composition of LB1148, the Company’s broad-spectrum serine protease inhibitor that acts to neutralize digestive enzymes, potentially reducing intestinal damage, until 2035.
See the rest here:
Palisade Bio Receives Canadian Patent Covering Composition of Lead Program in Development, LB1148
Recommendation and review posted by Fredricko
